Of note, in mantle cell lymphoma, it has also been previously demonstrated that, compared to wild type CCND1, n-terminal E36K, Y44D or C47S CCND1 mutations are likely oncogenic and increased cyclin D1 protein levels through attenuation of threonine-286 phosphorylation, thereby promoting resistance to ibrutinib, which is an FDA-approved Bruton tyrosine kinase inhibitor for mantle cell lymphoma treatment [27]. Here, CCND1 is linked to mantle cell lymphoma.